Well it looks like Livongo isn’t the only diabetes company using the current crisis to inflate the value of their shares, check this out;
“Nemaura Medical (NSDQ:NMRD) announced today that it is planning to immediately repurpose its SugarBeat continuous glucose monitor (CGM) as a continuous temperature monitor (CTM) to help diagnose fevers in potential cases of COVID-19.”
You can read the entire story at https://www.drugdeliverybusiness.com/nemaura-medical-repurposes-its-cgm-to-spot-coronavirus-fevers/
Before we go on we must admit we are disappointed that the normally well-respected Drug Delivery Business web . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.